0
M €
Gross Sales
+
0
%
European CNS market reached
+
0
CNS Molecules
Neuraxpharm is a European leader in pharmaceuticals for disorders affecting the central nervous system (CNS). We are specialists in this field since 1985 and our more than 35 years’ experience bring a broad, unparalleled knowledge into our research and final products.
We are experts in improving existing pharmaceutical forms and upgrading new products with the aim to deliver relevant improvements in the life and wellbeing of patients with neurological and psychiatric disorders.
We are guided by excellence, scientific rigour, quality and perseverance.
We understand that central nervous system disorders greatly affect how a person feels, behaves, thinks and relates to others. Nothing motivates us more than enhancing their quality of life, and we work tirelessly, hand in hand with healthcare professionals and scientific communities across Europe.
Our portfolio comprises of more than 120 molecules, covering different options to treat Depression, Anxiety, Parkinson’s, Alzheimer’s, Epilepsy, Schizophrenia/Psychosis and other central nervous system disorders.
With a focus on CNS, we develop and commercialize established brands, value added medicines, generics, Consumer Healthcare products, medical cannabis, beyond-the-pill solutions (digital health and medical devices) and orphan drugs. We are continuously striving to offer a wide range of effective, high quality and affordable CNS treatment options in Europe.
with sales forces in our main EU markets to strengthen our international position as a leader in CNS
into a robust pipeline that broadens our CNS portfolio with differentiated products
with the European community of CNS patients and healthcare professionals
from our international portfolio through the B2B selling of FDFs and APIs
via backward integration and strengthening operational excellence within the company
with a strong focus on quality, collaboration and agility promoting smart solutions that differentiate us from our competitors
We have a direct presence in 20 countries in Europe, with teams that have deep expertise in the CNS market and are working tirelessly to cement relationships with healthcare professionals.
We work with partners from around the globe, sharing the benefits of our long heritage in mental health and the central nervous system together with a wide offering in ten additional therapeutic areas. We focus in particular on the development of value-added products.
We work with an innate passion and perseverance to move health forward for our customers and patients across the globe.
Our journey began in 2016 with the acquisition of Spanish and German companies specialised in CNS since 1985 with an impeccable track record and recognition among healthcare professionals.
An Italian company was acquired in 2017, bringing a unique expertise in nutraceuticals and consumer health products to the group, opening the way to a more direct relationship with the end consumer.
France and the United Kingdom were then incorporated in 2018, as an acquired company and new affiliate respectively.
In 2019, expert companies were acquired in Czechia, Slovakia, Hungary and Switzerland and the Polish and Portuguese affiliates were founded.
Austria, Poland and the Republic of Ireland were incorporated in 2020 as acquired companies.
The steep growth that drove Neuraxpharm’s direct presence in Europe from two to 13 countries in just four years will continue, given the team’s aim of bringing our pharmaceuticals to all those in need of high-quality yet affordable medicines.
2020 also witnessed the acquisition of the market-leading prescription brand Buccolam® including global rights from Takeda, the only buccal midazolam approved across Europe. Buccolam® is currently commercialised in 18 countries in Europe.
A new business unit, based in Stockholm, was established to cover the country markets of Sweden, Norway, Finland, Denmark and Iceland. Through this expansion, Neuraxpharm strengthens its position as the leading CNS specialist in Europe with a direct presence in 18 countries.
Our plan to become the No1 CNS Specialist in Europe continues with the expansion in Greece, through the purchase of the specialized company Brain Therapeutics. The year 2022 ends with our expansion into the Netherlands.
The affiliate in Belgium covers Belgium and Luxembourg, completing our presence in the Benelux and strengthening our footprint in Europe.
Vertically integrated value chain in an asset light business model
Neuraxpharm is vertically integrated from Molecule to Market, giving us, at the same time, the flexibility to launch value-added products swiftly and responding to market demand, while ensuring the highest quality standards and scientific solidity.
Neuraxpharm is vertically integrated from Molecule to Market
Internal know-how across the whole value chain enabling strong flexibility and insight
Join our mailing list
Get the latest updates from the Neuraxpharm.